Clover Health Investments (NASDAQ:CLOV) Insider Karen Soares Sells 19,275 Shares of Stock

Clover Health Investments, Corp. (NASDAQ:CLOV) insider Karen Soares sold 19,275 shares of the business’s stock in a transaction that occurred on Tuesday, October 20th. The shares were sold at an average price of $4.66, for a total value of $89,821.50. Following the transaction, the insider owned 1,573,423 shares of the company’s stock, valued at $7,332,151.18. This represents a 1.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Karen Soares also recently made the following trade(s):

• On Thursday, October 15th, Karen Soares sold 14,673 shares of Clover Health Investments stock. The stock was sold at an average price of $4.68, for a total value of $68,669.64.
• On Tuesday, September 15th, Karen Soares sold 6,846 shares of Clover Health Investments stock. The stock was sold at an average price of $4.78, for a total value of $32,723.88.

Clover Health Investments Price Performance

Shares of NASDAQ CLOV opened at $4.80 on Wednesday. Clover Health Investments, Corp. has a 1-year low of $1.58 and a 1-year high of $5.59. The business’s fifty day moving average price is $4.46 and its two-hundred day moving average price is $4.05. The firm has a market capitalization of $2.55 billion, a PE ratio of -95.98 and a beta of 2.45.

Clover Health Investments (NASDAQ:CLOV) last posted its earnings results on Wednesday, August 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.01. Clover Health Investments had a negative return on equity of 4.20% and a negative net margin of 0.74%. The company had revenue of $743.17 million for the quarter, compared to analysts’ expectations of $728.27 million. Equities research analysts expect that Clover Health Investments, Corp. will post 0.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Canaccord Genuity Group lifted their price objective on shares of Clover Health Investments from $4.20 to $5.50 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Clover Health Investments in a research note on Monday, September 21st. Zacks Research upgraded shares of Clover Health Investments to a “hold” rating in a research report on Monday, September 14th. Deutsche Bank Aktiengesellschaft began coverage on shares of Clover Health Investments in a research note on Thursday, September 10th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Wall Street Zen lowered shares of Clover Health Investments from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 16th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $4.75.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio acquired a new position in shares of Clover Health Investments during the second quarter valued at $42,000. Nykredit A S bought a new stake in shares of Clover Health Investments during the second quarter valued at about $45,000. Ballew Advisors Inc bought a new stake in shares of Clover Health Investments during the third quarter valued at about $44,000. Nisa Investment Advisors LLC lifted its holdings in Clover Health Investments by 223.4% in the third quarter. Nisa Investment Advisors LLC now owns 10,855 shares of the company’s stock worth $47,000 after purchasing an additional 7,498 shares during the period. Finally, WNY Asset Management LLC acquired a new stake in Clover Health Investments in the second quarter worth about $69,000. Institutional investors and hedge funds own 19.77% of the company’s stock.

Clover Health Investments News Summary

Here are the key news stories impacting Clover Health Investments this week:

• Positive Sentiment: Clover Health earned top distinctions in U.S. News & World Report’s 2027 Medicare Advantage ratings across New Jersey, Georgia, and South Carolina. The recognition may support member growth, plan appeal, and the company’s competitive positioning in key markets. Clover Health Medicare Advantage ratings announcement
• Positive Sentiment: Institutional ownership activity was broadly constructive. Bank of New York Mellon, Tidal Investments, and Winton Group opened new positions, while California State Teachers Retirement System and AXQ Capital increased their holdings. Hedge funds and other institutions own approximately 19.77% of CLOV’s shares.
• Neutral Sentiment: Recent analyst views remain mixed. Deutsche Bank initiated coverage with a Buy rating and a $6.00 price target, while UBS raised its target to $5.00 but maintained a Neutral rating. The overall consensus remains Hold, with an average target of $4.75.
• Negative Sentiment: Several insiders reported sales: CEO Andrew Toy sold 62,176 shares, CEO Conrad Wai sold 23,627 shares, and Karen Soares sold a combined 33,948 shares. The transactions totaled roughly $469,000 based on the reported sale prices and modestly reduced their holdings.
• Negative Sentiment: The insider sales were executed under pre-arranged Rule 10b5-1 plans; the earlier transactions were specifically used to cover tax-withholding obligations related to equity vesting. This reduces their usefulness as a bearish signal, although repeated insider selling can still weigh on sentiment. Clover Health SEC insider filing

Clover Health Investments Company Profile

Clover Health Investments, Corp. is a health insurance technology company focused on providing Medicare Advantage plans to eligible seniors in the United States. Its plans combine hospital, medical and prescription drug coverage with additional benefits that may vary by plan and location.

The company uses its Clover Assistant technology platform to provide physicians with data-driven insights intended to support clinical decision-making and care coordination. The platform aggregates member health information and helps participating providers identify care opportunities, manage chronic conditions and engage with patients.

Clover Health was founded in 2012 and became a publicly traded company in 2021 through a merger with a special purpose acquisition company.